Journal: Frontiers in Pharmacology
Article Title: Treatment of Spleen-Deficiency Syndrome With Atractyloside A From Bran-Processed Atractylodes lancea by Protection of the Intestinal Mucosal Barrier
Figure Lengend Snippet: Identification of AA as the active ingredient in crude and bran-processed Atractylodes lancea . Model: SDS model rats group; M + Crude: SDS model rats administrated with crude AL extraction; M + Bran-processed: SDS model rats administrated with BAL extraction. (A) HPLC-ELSD chromatogram of the 50% EtOH extraction from AL (black) and BAL (red), the content of AA increased by 191.22% in the bran-processed Atractylodes lancea . (B) and (C) Comparison of the intestinal propulsion rate and GAS in SDS rats treated with crude and bran-processed Atractylodes lancea extracts. (D) 3D structure of AA. Data represented mean ± SD. Results are expressed as the mean ± SD from at least three independent experiments. * p
Article Snippet: HPLC-ELSD analysis was performed using an Agilent-1260 system coupled to a Welch HPLC C18 column (4.6 mm × 250 mm, 5 μm) maintained at 30 °C (injection volume, 20 μL).
Techniques: High Performance Liquid Chromatography